文献速递新药、器械与细胞基因治疗研发临床试验与 GCP基础与转化研究

DB-OTO基因治疗用于遗传性耳聋

DB-OTO Gene Therapy for Inherited Deafness.
PubMed 文献 · N Engl J Med · 2025-10-12

这项开放标签、单组、首次人体注册研究评估了DB-OTO双腺相关病毒1基因疗法治疗OTOF变异所致先天性深度耳聋儿童。12名儿童接受耳蜗内输注DB-OTO(每耳7.2×10^12个载体基因组),第24周时9/12(75%;95%CI 43-95;P=1.1×10^-13)达到行为纯音测听平均阈值≤70 dB HL的主要终点且听性脑干反应阈值≤90 dB nHL的关键次要终点。结论认为DB-OTO基因治疗改善了OTOF相关耳聋患者的听力,使3/12患者听力敏感度恢复正常。

要点

  • 12名OTOF变异所致深度耳聋儿童接受DB-OTO耳蜗内输注,9/12达到主要疗效终点。
  • 第24周9/12(75%)纯音测听平均阈值≤70 dB HL且听性脑干反应≤90 dB nHL。
  • 6名参与者无需辅助设备可听到轻声言语,3名听力敏感度恢复正常。

核心结论

  • DB-OTO基因治疗改善了OTOF相关耳聋患者的听力,使12名受治患者中3名的听力敏感度恢复正常。

研究设计与样本

  • 开放标签、单组、首次人体注册研究,纳入12名OTOF变异所致深度耳聋(平均听阈>90 dB HL)儿童,单次耳蜗内输注DB-OTO(每耳7.2×10^12个载体基因组),可单耳或双耳给药。

主要发现

  • 第24周时,12名参与者中9名(75%;95%CI 43-95;两个终点均为P=1.1×10^-13)达到纯音测听平均阈值≤70 dB HL的主要终点和听性脑干反应≤90 dB nHL的关键次要终点。
  • 6名参与者无需辅助设备可听到轻声言语,3名听力敏感度恢复正常。
  • 治疗期间或治疗后共发生或加重67例不良事件,均未导致退出研究。

关键数值与推荐

  • 主要疗效终点为第24周行为纯音测听平均阈值≤70 dB HL。
  • 关键次要终点为第24周对喀呖声刺激的听性脑干反应阈值≤90 dB nHL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genetic deficiency of otoferlin, a protein critical to synaptic transmission by the sensory hair cells of the ear, causes congenital deafness. Medicines to treat the condition are lacking; children typically receive cochlear implants. DB-OTO is a dual adeno-associated virus 1 gene therapy that delivers human OTOF complementary DNA (encoding otoferlin) regulated by a hair cell-specific promoter. METHODS: We conducted an open-label, single-group, first-in-human registrational study to evaluate DB-OTO. Children with OTOF variants and profound deafness (defined by an average audiometric threshold of >90 decibel hearing level [dB HL], indicating an inability to hear a gas-powered lawn mower) received an intracochlear infusion of DB-OTO (7.2×1012 vector genomes per ear) in one or both ears. The primary efficacy end point was an average threshold on behavioral pure-tone audiometry (PTA) at week 24 of 70 dB HL or less, a clinical standard that generally avoids cochlear implantation and enables natural acoustic hearing. A key secondary end point was the presence of an auditory brain-stem response to a click stimulus at a threshold at or below 90 dB normalized hearing level (db nHL) at week 24. Safety assessments included adverse events, laboratory results, and vestibular testing. RESULTS: A total of 12 children have been enrolled in the study. After a single infusion of DB-OTO, a PTA average threshold of 70 dB HL or less at week 24 (primary end point) and an auditory brain-stem response at or below 90 dB nHL (key secondary end point) were found in 9 of the 12 participants (75%; 95% confidence interval, 43 to 95; P = 1.1×10-13 for both end points). Six participants could hear soft speech without assistive devices, and 3 had average normal hearing sensitivity. A total of 67 adverse events occurred or worsened during or after treatment, none of which led to discontinued participation in the study. CONCLUSIONS: DB-OTO gene therapy improved hearing in patients with OTOF-related deafness, enabling natural acoustic hearing and normalizing hearing sensitivity in 3 of 12 treated patients. (Funded by Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT05788536.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Valayannopoulos V, Bance M, Carvalho DS, et al. DB-OTO Gene Therapy for Inherited Deafness. N Engl J Med. 2025. PMID: 41085057. doi:10.1056/NEJMoa2400521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。